Lenalidomide
![ASCO 2023: Empowering Responses in Follicular Lymphoma: Epcoritamab Combines with Rituximab and Lenalidomide to Unleash Promising Outcomes](https://pharmtales.com/wp-content/uploads/2023/06/ASCO-2023_-Empowering-Responses-in-Follicular-Lymphoma_-Epcoritamab-Combines-with-Rituximab-and-Lenalidomide-to-Unleash-Promising-Outcomes.jpg)
ASCO 2023: Empowering Responses in Follicular Lymphoma: Epcoritamab Combines with Rituximab and Lenalidomide to Unleash Promising Outcomes
SG Tylor
ABSTRACT NUMBER: 7506 Epcoritamab, a novel bispecific antibody targeting CD3 and CD20, has demonstrated potent T-cell-mediated cytotoxic activity against CD20-positive ...